Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003;5 Suppl 8(Suppl 8):S37-41.

Overactive bladder in special patient populations

Overactive bladder in special patient populations

Rodney A Appell. Rev Urol. 2003.

Abstract

It is now well accepted that overactive bladder (OAB) negatively affects the quality of life of a large number of persons and that the primary mode of therapy is the use of medication-currently antimuscarinic agents. However, it is also important for physicians to understand how the use of these drugs affects specific groups of patients. Most of the concern in this area focuses on the potential for these populations to experience certain adverse events or side effects from the use of antimuscarinic agents; this has prevented these drugs from being prescribed in these populations to the same degree as in the general population of OAB sufferers. The purpose of this article is to review these specific populations of OAB patients, including pediatric, geriatric, and pregnant patients, men with prostate problems, and patients in whom OAB is of neurogenic origin, and to discuss what is currently known about the use of antimuscarinic agents in these groups.

PubMed Disclaimer

References

    1. Aubert D, Cencig P, Royer M. Treatment with oxybutynin hydrochloride of urinary incontinence and hyperactive bladder conditions in children. Ann Pediatr (Paris) 1986;33:629–634. - PubMed
    1. Kaplinsky R, Greenfield S, Wan J, et al. Expanded followup of intravesical oxybutynin chloride use in children with neurogenic bladder. J Urol. 1996;156:753–756. - PubMed
    1. Appell RA, Chancellor MB, Zobrist RH, et al. Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects. Mayo Clin Proc. 2003;78:696–702. - PubMed
    1. Hjalmas K, Hellstrom AL, Mogren K, et al. The overactive bladder in children: a potential future indication for tolterodine. BJU Int. 2001;87:1–7. - PubMed
    1. Goessl C, Sauter T, Michael T, et al. Efficacy and tolerability of tolterodine in children with detrusor hyperreflexia. Urology. 2000;55:414–418. - PubMed

LinkOut - more resources